FUJIFILM Diosynth Biotechnologies held a ribbon-cutting ceremony on Monday to celebrate the opening of a 62,000-square-foot facility in Morrisville to house its bioprocess R&D groups.
The FUJIFILM site conducts contract development and manufacturing of recombinant biopharmaceuticals including proteins, vaccines and monoclonal antibodies.
“The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients,” said Steve Bagshaw, CEO.
The new building, called the BioProcess Innovation Center, houses the company’s process and analytical R&D, process sciences and stability groups.
“The design of the facility reflects our core philosophy of cross-functional collaboration to research and process development which is a key differentiator of our company,” said President Martin Meeson.
The project developer was Alexandria Real Estate Equities, and the general contractor was KBR Building Group. The facility is at 6051 George Watts Hill Drive.
The company’s facilities in North Carolina, Texas and England employ about 1,000 people. The other sites are FUJIFILM Diosynth Biotechnologies UK Limited, in Billingham, England, and FUJIFILM Diosynth Biotechnologies Texas, LLC in College Station.
Their parent company, FUJIFILM Holdings Corporation, of Tokyo, is a global conglomerate involved in healthcare with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat-panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products.
(C) N.C. Biotechnology Center
